Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2384
Source ID: NCT00772174
Associated Drug: Pioglitazone And Metformin
Title: Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes
Acronym: PRISMA
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Pioglitazone and Metformin|DRUG: Metformin
Outcome Measures: Primary: Increase in High-Density Lipoprotein cholesterol levels., Final Visit. | Secondary: The change from Baseline in Metabolic Syndrome, as defined by the International Diabetes Federation (aggregate waist circumference, fasting plasma glucose, triglycerides and high-density lipoprotein cholesterol)., Weeks: 8 and 24.|The change from Baseline in Metabolic Syndrome, as defined by the International Diabetes Federation (blood pressure)., At all Visits.|The change from Baseline in Individual Metabolic Parameters (insulin sensitivity and beta-cell function, inflammatory cytokines, adipokines, endothelial functionality)., Weeks: 8 and 24.|Adverse Events., At all Visits.|The change from Baseline in Laboratory Parameters (hematology, chemistry and urinalysis)., Weeks: 8 and 24.
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 418
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2007-01
Completion Date: 2008-02
Results First Posted:
Last Update Posted: 2010-07-05
Locations:
URL: https://clinicaltrials.gov/show/NCT00772174